We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks 2nd on this list. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Pfizer said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over ...

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...

CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...

Stocks extended their rally Thursday, even as oil prices gained, amid continued optimism among traders that the fragile two-week ceasefire between the U.S. and Iran could be sustained. The S&P 500 ...

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) -Acoramidis mitigated the rise in NT-proBNP through Month ...

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...